FDA allows Teva to file allergic rhinitis drug NDA
The NDA is supported by the results of two Phase III clinical trials evaluating the efficacy and safety of BDP Nasal HFA which showed improvement in nasal symptoms
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.